Paule B, Quillard J, Medicis P, Bourgeois P, Grossin M, Bisson M, Kahn M F
Service de Rhumatologie, Hôpital de Bicêtre, Le-Kremlin-Bicêtre.
Rev Rhum Mal Osteoartic. 1988 Jan;55(1):27-32.
The prognostic value of bone marrow biopsy was established in 31 patients suffering from stage IIA and IIIA myeloma (Durie and Salmon classification). Data obtained from quantitative marrow cytology permit to differentiate 3 sub-groups of cells: plasmocytes, plasmoblasts, plasmocytes/plasmoblasts of which the incidence on the prognosis and the response to treatment was studied. There is a correlation between the response to MP and the nature of various cells populations and, on the other hand, the type of infiltration. A sub-group of patients, resisting to MP, was identified: diffuse plasmoblastic myelomas of poor prognosis. Induction poly-chemotherapy seems far superior over the MP combination, which was always a controverted issue.
对31例IIA期和IIIA期骨髓瘤患者(Durie和Salmon分期)进行了骨髓活检的预后价值研究。从定量骨髓细胞学获得的数据能够区分3种细胞亚群:浆细胞、成浆细胞、浆细胞/成浆细胞,并研究了它们在预后和治疗反应方面的发生率。MP治疗反应与各种细胞群体的性质以及浸润类型之间存在相关性。确定了一组对MP耐药的患者:预后不良的弥漫性成浆细胞骨髓瘤。诱导多药化疗似乎远优于MP联合方案,这一直是一个有争议的问题。